Acute and long-term effects of zoledronate in adult patients with osteogenesis imperfecta. An observational Spanish study with five years of follow-up.

Isabel Pavón de Paz,José Antonio Rosado Sierra,Carmen Pérez Blanco,Naiara Modroño Móstoles,Guadalupe Guijarro de Armas,Cristina Navea Aguilera

Endocrinología, Diabetes y Nutrición (English ed.)（2019）

Cited 1|Views4

No score

Abstract

Osteogenesis imperfecta (OI) is an inherited disorder that causes low mineral density and bone fragility. Previous studies have shown the efficacy of bisphosphonates to increase bone mineral density (BMD). This study assessed changes over time in BMD and biochemical markers of bone metabolism in adult patients with osteogenesis imperfecta treated with intravenous zoledronic acid and the safety of this treatment.

Translated text

Key words

Osteogenesis imperfecta,Treatment,Adults,Zoledronic acid,Bone mineral density

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined